AI adoption in veterinary clinics rose from 39 percent to 84 percent in two yearsResting cortisol tracked APPLE scores but not mortality in 30 SIRS dogsFetch Pet Insurance bundles four annual telehealth visits into every policy at no added premiumPregabalin before spay raised sedation scores 2.46 points in 54 catsParasight System wins preferred-provider deal with 850-hospital independent practice networkVeterinary economist Matt Salois says practices cannot rely on pricing growth into 2027WSAVA publishes updated dental guidelines with trauma and radiographic sectionsDechra launches Laverdia, the first FDA-approved oral treatment for canine lymphomaAI adoption in veterinary clinics rose from 39 percent to 84 percent in two yearsResting cortisol tracked APPLE scores but not mortality in 30 SIRS dogsFetch Pet Insurance bundles four annual telehealth visits into every policy at no added premiumPregabalin before spay raised sedation scores 2.46 points in 54 catsParasight System wins preferred-provider deal with 850-hospital independent practice networkVeterinary economist Matt Salois says practices cannot rely on pricing growth into 2027WSAVA publishes updated dental guidelines with trauma and radiographic sectionsDechra launches Laverdia, the first FDA-approved oral treatment for canine lymphoma
The WireBy The VeterinaryPracticeNow Desk3 min readAugust 14, 2026
Which Adequan lots have glass fibers, and what you tell the clients who already got them
Four lots pulled after glass fibers found in samples. If you used them, here's the documentation and client-communication call.
American Regent pulled four lots of Adequan injectable after finding glass fibers in retained samples, and if you stocked any of those lots and already used them, you have documentation work ahead of you.
The plain answer
The recall covers "two lots of Adequan Canine Injection (100 mg/mL, 5 mL multi-dose vials) for dogs, lots 25011 and 3369, and two lots of Adequan i.m. Injection (500 mg/5 mL, single-dose vials) for horses, lots 24416 and 25265P," according to the company. American Regent detected the glass fibers in internally retained samples, not from field complaints. According to Veterinary Practice News, "no adverse events associated with the recalled lots had been reported at the time of the recall."
According to the company, "administration of an injectable product containing particulate matter such as glass fibers may cause local irritation, swelling, inflammation, injection-site pain, infection or abscess formation." Veterinary Practice News reports the recalled products were distributed nationwide "to veterinary practices, distributors, wholesalers and online pharmacies."
The caveat that makes it hard
If you injected doses from any of these four lots, you now face a documentation decision and likely a client-communication one. The FDA announcement directs veterinary professionals to "verify product lot numbers and follow recall instructions before administering affected products," according to Veterinary Practice News, but the guidance stops at future doses.
Adequan is commonly used in canine orthopedic cases and equine performance work. The FDA announcement does not specify what practices should do about doses already administered from the recalled lots.
Pull stock today. Check your inventory against the four lot numbers. If you have any of the recalled lots, quarantine them and follow American Regent's return instructions.
Review invoices to identify affected patients. Cross-reference your dispensing records or injection logs against the recalled lot numbers. Build a list of every patient who received a dose from one of these lots, with the date of administration. This is the documentation you'll want if questions surface later.
Decide your client-communication approach. You have two options: proactively contact affected clients to inform them of the recall and the symptoms to watch for, or wait for symptoms and respond reactively. The first option takes time and may concern clients whose animals show no adverse effects. The second option defers the work but carries the risk that a client learns about the recall from another source and wonders why you didn't call. We'd lean toward proactive outreach and documenting every attempt, even if the client does not answer.
Document the whole chain. Record the date you received the recall notice, the date you pulled stock, the patient list, the outreach attempts, and any client responses. If questions surface later, the record of what you knew and when you acted needs to be in writing.
According to Veterinary Practice News, "Adequan Canine is prescribed for the treatment of noninfectious degenerative or traumatic joint dysfunction in dogs" while "Adequan i.m. is used in horses for similar joint conditions and associated lameness. Both products are administered intramuscularly by or under the direction of a licensed veterinarian," which means the injection and the recall response both fall inside your scope.
The FDA announcement does not specify what practices should do about doses already administered from the recalled lots.
The risk in waiting
No adverse events had been reported at the time of the recall, which means the glass-fiber contamination was caught in quality-control samples, not in the field. That is good news for patient safety, but it does not eliminate the documentation question. If you used a recalled lot and a client's animal later develops an injection-site reaction, you'll want a record showing you acted when you learned about the recall.
The FDA announcement is posted on the agency's website. The safest play: document what you did and when, and consider whether proactive client contact makes sense for your practice and your relationship with the affected clients.
Get the next issue in your inbox. Free, weekly, no fluff.
